

PrEP@PIMAN

QUANHATHAI KAEWPOOWAT, MD

Research Physician

Research Institute for Health Sciences

PIMAN Clinic

- HIV Voluntary Counseling and Testing (VCT) for MSM
 - Bisexual, TG and Gay men
 - For Free!
- Run by Research Institute for Health Sciences
 - Skilled nurses (counsellors) and physician
- Located at Nimman Soi 13
- www.pimancenter.com
- <https://www.facebook.com/PimancenterChiangmai>





ห้องให้คำปรึกษา

Our Ongoing Project: PrEP@PIMAN

- **Objective:** การศึกษาการยอมรับต่อการรับประทานยาต้านไวรัสล่วงหน้าเพื่อป้องกันการติดเชื้อเอชไอวีในกลุ่มชายที่มีเพศสัมพันธ์กับชายและสาวประเภทสอง

Rationale and recruitment plan

Global/Thailand HIV incidence and prevalence

Global summary of the AIDS epidemic | 2014

Number of people living with HIV in 2014	Total	36.9 million	[34.3 million – 41.4 million]
	Adults	34.3 million	[31.8 million – 38.5 million]
	Women	17.4 million	[16.1 million – 20.0 million]
	Children (<15 years)	2.6 million	[2.4 million – 2.8 million]

People newly infected with HIV in 2014	Total	2.0 million	[1.9 million – 2.2 million]
	Adults	1.8 million	[1.7 million – 2.0 million]
	Children (<15 years)	220 000	[190 000 – 260 000]

AIDS deaths in 2014	Total	1.2 million	[980 000 – 1.6 million]
	Adults	1.0 million	[890 000 – 1.3 million]
	Children (<15 years)	150 000	[140 000 – 170 000]


- THAILAND




- Estimated people living with HIV in 2015: 1.5 millions
 - Estimated total population > 65 m
 - PLWH = 2.3%
 - 85% = 15-45 y/o
- New HIV infection in 2015: ~ 7000
- Mortality in 2015: ~ 16,000

HIV Statistic by groups

Figure 1. HIV Diagnoses by Transmission Category, 2005-2014




Data source: CDC.gov




J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):19953.


Prevention Strategy



Unexposed



Exposed
(pre-coital)




Exposed
(post-coital)



GOAL



HIV Infection



การศึกษา	กลุ่มประชากร	ยาที่ใช้	ประสิทธิผลโดยรวม	Adherence โดยรวม	ประสิทธิผลเมื่อ Adherence สูง
IPIRGAY	MSM	FTC/TDF	86%		
PROUD	MSM	FTC/TDF	86%	-	-
Partner PrEP	Serodiscordant heterosexual	FTC/TDF TDF		81%	90% 86%
TDF2	Heterosexual men & women			79%	78%
iPrEX			44%	51%	92%
Bangkok TDF	IVL	TDF	49%	84%	74%
FEM PrEP	Women	FTC/TDF	6%	35-38%	No protection
VOICE	Women	FTC/TDF TDF	-4% -49%	<30%	No protection

PrEP works!!!

PrEP is widely accepted!

US Public Health Service

PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE UNITED STATES - 2014

A CLINICAL PRACTICE GUIDELINE




Increasing PrEP Use

A focused effort by New York State

to increase PrEP uptake started
in June 2014 and included:

1. **Provider Training**
2. **Raising Awareness**
3. **Ensuring Medicaid Coverage**

Number of
New York
State Medicaid
beneficiaries
receiving PrEP.



SOURCE: NYS Medicaid Data Warehouse (based on Medicaid data loaded through July 2015).

In 2015, WHO recommends that PrEP should be considered for people at substantial risk of acquiring HIV as part of HIV prevention

GUIDELINES



GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND ON PRE-EXPOSURE PROPHYLAXIS FOR HIV

SEPTEMBER 2015




World Health
Organization



PrEP@PIMAN – Demonstration Project


“Real life” situation



Number of participants = 200

PrEP@PIMAN:

SCREENING



≥ 18 y/o



HIV NEGATIVE

SAFETY LABS



HBs Ag = neg




PHYSICIAN EVAL



ENROLLMENT



PrEP



Any prescribing health care provider can deliver PrEP care.



SOURCE: 2014 PrEP Clinical Practice Guidelines.

Have questions?

Read the full 2014 PrEP Clinical Practice Guidelines:
www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf

Call the PrEP Clinician Helpline:
 (855) 448-7737
 or (855) HIV-PrEP



WHY
THIS PILL
CAN CHANGE YOUR LIFE.



HUMAN
RIGHTS
CAMPAIGN®

thank you



© 1996, 2002 SANRIO CO., LTD.

THANK YOU 😊

PrEP Efficacy

Study (location)	Population	Design	Relative reduction in HIV incidence in intention-to-treat analysis	PrEP detection in blood samples from non-seroconverters
Completed trials (ordered by decreasing HIV risk reduction in primary intention-to-treat analysis)				
Partners PrEP Study (Kenya, Uganda)	4747 heterosexual men and women with HIV infected partners (serodiscordant couples)	1:1:1 randomization to daily oral TDF, FTC/TDF, or placebo	TDF: 67% (95% CI 44-81%, p<0.0001) FTC/TDF: 75% (95% CI 55-87%, p<0.0001)	82% Detection of tenofovir in blood associated with 86-90% HIV protection.
TDF2 Study (Botswana)	1219 heterosexual men and women	1:1 randomization to daily oral FTC/TDF or placebo	FTC/TDF: 63% (95% CI 22-83%, p=0.01)	79%
iPrEx (Brazil, Ecuador, Peru, South Africa, Thailand, US)	2499 MSM and transgender women	1:1 randomization to daily oral FTC/TDF or placebo	FTC/TDF: 44% (95% CI 15-63%, p=0.005)	51% Detection of tenofovir associated with 92% HIV protection, high adherence with >95% protection.
CAPRISA 004 (South Africa)	889 women	1:1 randomization to intercourse-associated use of tenofovir vaginal gel or placebo	Tenofovir gel: 39% (95% CI 6-60%, p=0.02)	Detection of high concentrations of tenofovir (>1000 ng/mL) in cervicovaginal fluid associated with 74% reduced HIV risk.
FEM-PrEP (Kenya, South Africa, Tanzania)	2120 women	1:1 randomization to daily oral FTC/TDF or placebo	FTC/TDF: No HIV protection	35-38% at a single visit, 26% at two consecutive visits
VOICE (South Africa, Uganda, Zimbabwe)	5029 women	1:1:1:1 randomization to daily oral TDF, FTC/TDF, oral placebo, tenofovir vaginal gel, or gel placebo	TDF: No HIV protection FTC/TDF: No HIV protection Tenofovir gel: No HIV protection	≤30% of samples had tenofovir detected, ≥50% of women in each of the active arms <u>never</u> had tenofovir detected, at any time during their follow-up
Trials in progress				
Bangkok Tenofovir Study (Thailand)	2413 injection drug users	1:1 randomization to daily oral TDF or placebo	TDF: Results expected 2013.	Not available
IPERGAY (France, Canada)	1900 men who have sex with men	1:1 randomization to FTC/TDF or placebo, used with intercourse	FTC/TDF: Results expected 2016.	Not available

- Efficacy > 90% (if taking meds every day!!)

ตารางที่ 7.1 ประสิทธิภาพของ PrEP จากการศึกษาในกลุ่มประชากรต่างๆ แสดงตาม adherence ในการกินยา

การศึกษา	กลุ่มประชากร	ยา PrEP ที่ใช้	ประสิทธิภาพโดยรวม	Adherence ในการศึกษา	ประสิทธิภาพเมื่อมี adherence สูง
Partners PrEP	Serodiscordant heterosexual couples	FTC/TDF TDF	75% 61%	11% 51%	90% 86%
TDF2	Heterosexual men and women	FTC/TDF	78%		78%
iPrEX	Men who have sex with men	TDF	74%	51%	92%
Bangkok TDF	Men who have sex with men	TDF	49%	84%	74%
FEM-PrEP	Women	FTC/TDF	6%	35-38%	No protection
VOICE	Women	FTC/TDF TDF	-4% -49%	< 30%	No protection No protection

PrEP works!!!

